Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
VNDA Vanda Pharmaceuticals
Post Mkt Price
Do not show
Hide blank lines
Total revenue
-5.17% 64.39M -3.95% 60.19M 8.27% 268.68M 0.54% 68.02M
Operating revenue
-5.17% 64.39M -3.95% 60.19M 8.27% 268.68M 0.54% 68.02M
Cost of revenue
-7.72% 6.06M -6.05% 5.67M 9.69% 25.63M -2.74% 6.24M
Gross profit
-4.89% 58.33M -3.73% 54.53M 8.12% 243.05M 0.89% 61.78M
Operating expense
12.06% 54.87M 34.34% 62.2M 1.68% 200.89M 4.64% 53.15M
Selling and administrative expenses
16.42% 33M 37.09% 40.85M -11.72% 124.05M -5.97% 33.45M
Research and development costs
6.13% 21.49M 29.99% 20.97M 35.6% 75.36M 30.18% 19.33M
Depreciation amortization depletion
2.71% 379K 2.43% 379K 0% 1.48M -0.27% 369K
-Depreciation and amortization
2.71% 379K 2.43% 379K 0% 1.48M -0.27% 369K
Operating profit
-72.02% 3.46M -174.16% -7.67M 54.8% 42.17M -17.37% 8.64M
Net non-operating interest income expense
Other net income (expense)
40% 329K 20.69% 105K -95.49% 199K -105.5% -26K
Other non- operating income (expenses)
40% 329K 20.69% 105K -95.49% 199K -105.5% -26K
Income before tax
-69.93% 3.79M -172.54% -7.56M 33.83% 42.36M -21.18% 8.61M
Income tax
-58.79% 1.22M -163.78% -1.13M 10.75% 9.21M -43.96% 1.53M
Net income
-73.33% 2.57M -174.34% -6.43M 42.06% 33.15M -13.58% 7.08M
Net income continuous Operations
-73.33% 2.57M -174.34% -6.43M 42.06% 33.15M -13.58% 7.08M
Minority interest income
Net income attributable to the parent company
-73.33% 2.57M -174.34% -6.43M 42.06% 33.15M -13.58% 7.08M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
-73.33% 2.57M -174.34% -6.43M 42.06% 33.15M -13.58% 7.08M
Basic earnings per share
-70.59% 0.05 -168.75% -0.11 39.53% 0.6 -13.33% 0.13
Diluted earnings per share
-70.59% 0.05 -173.33% -0.11 38.1% 0.58 -14.29% 0.12
Dividend per share
Currency Unit
Accounting Standards
Audit Opinions
----Unqualified Opinion--

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company’s marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company’s products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
CEO: Polymeropoulos M.D., Mihael H.
Market: NASDAQ
Hot List
SymbolLatest price%Chg